Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851370 | 1.00 | KDM4E (0.57) | KDM4ELMNAADRA2AHIF1AADRA2C | |
| SCHEMBL11419589 | 1.00 | KDM4E (0.57) | KDM4ELMNAADRA2AHIF1AADRA2C | |
| SCHEMBL18082658 | 1.00 | KDM4E (0.57) | KDM4ELMNAADRA2AHIF1AADRA2C | |
| Hydrochloric Acid SCHEMBL6192973 | 0.98 | ALDH1A1 (0.59) | KDM4ELMNAADRA2AHIF1AADRA2C | |
| Hydrochloric Acid SCHEMBL836918 | 0.98 | ALDH1A1 (0.59) | KDM4ELMNAADRA2AHIF1AADRA2C | |
| SCHEMBL3695690 | 0.84 | CA1 (0.58) | CYP2D6ALDH1A1MAPK1TDP1AOC3 | |
| SCHEMBL11938486 | 0.84 | CA1 (0.58) | CYP2D6ALDH1A1MAPK1TDP1AOC3 | |
| SCHEMBL19728209 | 0.84 | CA1 (0.58) | CYP2D6ALDH1A1MAPK1TDP1AOC3 | |
| SCHEMBL11938484 | 0.84 | CA1 (0.58) | CYP2D6ALDH1A1MAPK1TDP1AOC3 | |
| SCHEMBL19728201 | 0.84 | CA1 (0.58) | CYP2D6ALDH1A1MAPK1TDP1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| WO-2007100880-A1 | CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007098214-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| EP-1286975-B1 | BICLYCLIC CYCLOHEXYLAMINES AND THEIR USE AS NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6794402-B2 | Bicyclic cyclohexylamines and their use as NMDA receptor antagonists | WARNER-LAMBERT COMPANY | 2004-09-21 | — | — | US | disclosed |
| US-20030236252-A1 | Bicyclic cyclohexylamines and their use as nmda receptor antagonists | NIKAM SHAM SHRIDHAR (US) | 2003-12-25 | — | — | US | disclosed |
| US-5329023-A | Method of preparing optically active alcohols which consist substantially or entirely of one enantiomer | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1994-07-12 | — | — | US | disclosed |
| EP-0322973-A2 | Method of preparing optically active cyanohydrin derivatives and their conversion products, and optically active compounds to be obtained in this manner | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1989-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | KDM4E 2365/4885LMNA 3728/4885ADRA2A 1604/4885 |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | KDM4E 2436/4885LMNA 4277/4885ADRA2A 1611/4885 |
| US-20030236252-A1 | Bicyclic cyclohexylamines and their use as nmda receptor antagonists | GRIN1, GRIN2C, GRIN2A | KDM4E 2103/4885LMNA 2062/4885ADRA2A 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.